MedTrace Logo

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

NCT07181239 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2025-09-18

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.

Conditions

  • Multiple Myeloma (MM)

Interventions

DRUG

CM336 Injection

Specified dose on specified days

DRUG

Standard Of Care( SOC)

Specified dose on specified days

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Principal Investigators

  • Lugui Qiu · Chinese Academy of Medical Sciences

  • Gang An · Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2027-09-30
Completion
2030-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07181239 on ClinicalTrials.gov